daunorubicin

P3, N=683, Recruiting, University Hospital Muenster | Trial completion date: Nov 2027 --> Apr 2030 | Trial primary completion date: Nov 2027 --> Apr 2030

P2, N=47, Active, not recruiting, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Active, not recruiting

P3, N=875, Recruiting, Stichting Hemato-Oncologie voor Volwassenen Nederland | N=423 --> 875

P2, N=318, Completed, Alliance for Clinical Trials in Oncology | Active, not recruiting --> Completed

P3, N=488, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Feb 2027

The patient received induction chemotherapy with cytarabine and daunorubicin along with localized radiotherapy. This case highlights the importance of considering hematologic malignancies in patients presenting with atypical or treatment-refractory scrotal swellings. Early biopsy and multidisciplinary evaluation are essential for timely diagnosis and appropriate management.

Based on these results, we found that SSI-4, an SCD1 inhibitor, could enhance chemosensitivity of daunorubicin (DNR), which can induce ferroptosis in tumor cells, effectively reduced the resistance to ferroptosis in AML cells exhibiting high ENO1 expression. Overall, our study elucidates the mechanism of ENO1 promotes SCD1 transcription, driving lipid reprogramming and ferroptosis resistance within AML. Additionally, it highlights the therapeutic potential of combining SCD1 inhibition with DNR for AML patients with elevated ENO1 expression levels.

The patient received azacitidine and venetoclax, with no response, followed by cytarabine and daunorubicin, with transient clinical improvement; however, progression to AML occurred within a few weeks. This case highlights the diagnostic challenge of hepatic MS presenting as refractory ascites, and supports consideration of early liver biopsy, with sampling from multiple sites, in patients with unexplained ascites and underlying hematologic abnormalities.

P1/2, N=30, Recruiting, OHSU Knight Cancer Institute | Trial primary completion date: Apr 2026 --> Dec 2026

The patient was treated with induction chemotherapy (7 + 3 regimen: daunorubicin and cytarabine), but her condition deteriorated, and she eventually succumbed to respiratory failure. This case highlights the importance of considering hematologic malignancy in the differential diagnosis of DAH, particularly in the absence of other identifiable causes.

The patient was treated with standard induction chemotherapy using the "7 + 3″ regimen consisting of cytarabine and daunorubicin. During treatment, she developed fever, jaundice, and profound pancytopenia, and on day 12 she suffered sudden cardiorespiratory arrest and died. This case underscores the diagnostic complexity of gastrointestinal myeloid sarcoma, highlights the importance of immunohistochemistry in distinguishing it from other malignancies, and emphasizes the aggressive clinical course and poor prognosis that may occur even in non-leukemic presentations.

P2/3, N=25, Recruiting, Medical University Of Lodz | Not yet recruiting --> Recruiting